Q: How does Ofatumumab work?

Targeting B Cells Ofatumumab is a type of medication known as a monoclonal antibody. These are laboratory-made proteins designed to recognize and bind to specific targets in the body. Ofatumumab specifically targets a protein called CD20, which is found on the surface of B-lymphocytes (B cells), a type of white blood cell. Mechanism of Action When ofatumumab attaches to the CD20 protein on a B cell, it triggers the body's immune system to attack and destroy that cell. This process helps manage conditions where B cells are either cancerous or overactive: Multiple Sclerosis (MS): In relapsing forms of MS, the immune system mistakenly attacks the protective coating of nerves. By reducing the number of B cells, ofatumumab helps prevent this immune-mediated damage. Chronic Lymphocytic Leukemia (CLL): In this type of cancer, the body produces too many abnormal B cells. Ofatumumab works by binding to these cancerous cells so the immune system can eliminate them from the blood and bone marrow. By lowering the levels of these specific cells, the medication helps reduce inflammation in MS and slows the progression of cancer in CLL.

Q: What are the brand names for Ofatumumab?

Ofatumumab is sold under the brand names Arzerra and Kesimpta .

Q: What are the active ingredients in Ofatumumab?

The active ingredient in Ofatumumab is ofatumumab .

Q: What are the side effects of Ofatumumab?

Common side effects of Ofatumumab may include: injection site reactions upper respiratory infection headache Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ofatumumab?

Ofatumumab belongs to the anti-CD20 monoclonal antibody drug class.

Q: Is Ofatumumab safe during pregnancy and breastfeeding?

Pregnancy There is limited information regarding the safety of ofatumumab during pregnancy. Because ofatumumab targets B-cells in the immune system, it may cause a reduction in B-cells in a developing fetus if used during pregnancy. Animal studies have shown that exposure to similar medications can lead to immune system issues in offspring. Healthcare providers generally recommend the following: Pregnancy Testing: A pregnancy test may be required before starting treatment to ensure you are not pregnant. Contraception: Use effective birth control during treatment and for at least 6 months after the final dose. Consultation: If you become pregnant or plan to become pregnant, talk to your doctor about the potential risks to the baby and the benefits of the treatment for your condition. Breastfeeding It is currently unknown if ofatumumab is excreted in human breast milk. While many large protein medications like ofatumumab are likely to be broken down in an infant's stomach, the potential for side effects in a nursing child has not been fully determined. Decisions regarding breastfeeding while on this medication should be made in consultation with a healthcare provider, weighing the necessity of the drug for the mother against the potential risks to the infant.

Q: What forms and strengths does Ofatumumab come in?

Ofatumumab is provided in the following delivery formats: Subcutaneous Injection: This form is available as a solution in single-dose prefilled autoinjector pens or single-dose prefilled syringes. It is designed for administration into the fatty tissue under the skin. Intravenous Infusion: This form is available as a concentrated solution in single-dose vials. It must be diluted by a healthcare professional before being administered directly into a vein.

Question 1

What is Ofatumumab?

Accepted Answer

Ofatumumab is a laboratory-made protein known as a monoclonal antibody. It is designed to recognize and attach to a specific protein called CD20 found on the surface of B lymphocytes, which are a type of white blood cell.

By binding to these cells, the medication helps the immune system identify and destroy them. This process reduces the number of circulating B cells involved in the progression of certain diseases.

Question 2

What is Ofatumumab used for?

Accepted Answer

Ofatumumab is used to treat relapsing forms of multiple sclerosis and chronic lymphocytic leukemia.

Question 3

How does Ofatumumab work?

Accepted Answer

Targeting B Cells

Ofatumumab is a type of medication known as a monoclonal antibody. These are laboratory-made proteins designed to recognize and bind to specific targets in the body. Ofatumumab specifically targets a protein called CD20, which is found on the surface of B-lymphocytes (B cells), a type of white blood cell.

Mechanism of Action

When ofatumumab attaches to the CD20 protein on a B cell, it triggers the body's immune system to attack and destroy that cell. This process helps manage conditions where B cells are either cancerous or overactive:

Multiple Sclerosis (MS): In relapsing forms of MS, the immune system mistakenly attacks the protective coating of nerves. By reducing the number of B cells, ofatumumab helps prevent this immune-mediated damage.
Chronic Lymphocytic Leukemia (CLL): In this type of cancer, the body produces too many abnormal B cells. Ofatumumab works by binding to these cancerous cells so the immune system can eliminate them from the blood and bone marrow.

By lowering the levels of these specific cells, the medication helps reduce inflammation in MS and slows the progression of cancer in CLL.

Question 4

What are the brand names for Ofatumumab?

Accepted Answer

Ofatumumab is sold under the brand names Arzerra and Kesimpta.

Question 5

What are the active ingredients in Ofatumumab?

Accepted Answer

The active ingredient in Ofatumumab is ofatumumab.

Question 6

What are the side effects of Ofatumumab?

Accepted Answer

Common side effects of Ofatumumab may include:

injection site reactions
upper respiratory infection
headache

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Ofatumumab?

Accepted Answer

Ofatumumab belongs to the anti-CD20 monoclonal antibody drug class.

Question 8

What is the dosage of Ofatumumab and how do I take it?

Accepted Answer

Administration Methods

Ofatumumab is available in two different forms. One form is administered as an injection under the skin (subcutaneous), and the other is given as an infusion into a vein (intravenous).

Subcutaneous Injection

When used for certain conditions, ofatumumab is provided in a prefilled pen or syringe for injection under the skin. The treatment typically begins with several initial weekly doses, followed by a break, and then transitions to a regular monthly maintenance schedule. Injections are usually given in the abdomen, thigh, or outer upper arm. It is important to rotate injection sites and avoid areas where the skin is tender, bruised, red, or hard.

Intravenous Infusion

For other conditions, ofatumumab is administered as a slow infusion into a vein by a healthcare professional in a clinical setting. The schedule for these infusions is determined by a healthcare provider based on the treatment plan. Patients may receive other medications, such as corticosteroids or antihistamines, before the infusion to help reduce the risk of infusion-related reactions.

Missed Doses

If a subcutaneous injection is missed, it should be administered as soon as it is remembered. After the missed dose is taken, the regular monthly schedule should be resumed. If an appointment for an intravenous infusion is missed, the healthcare provider should be contacted immediately to reschedule the treatment.

Question 9

Is Ofatumumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the safety of ofatumumab during pregnancy. Because ofatumumab targets B-cells in the immune system, it may cause a reduction in B-cells in a developing fetus if used during pregnancy. Animal studies have shown that exposure to similar medications can lead to immune system issues in offspring.

Healthcare providers generally recommend the following:

Pregnancy Testing: A pregnancy test may be required before starting treatment to ensure you are not pregnant.
Contraception: Use effective birth control during treatment and for at least 6 months after the final dose.
Consultation: If you become pregnant or plan to become pregnant, talk to your doctor about the potential risks to the baby and the benefits of the treatment for your condition.

Breastfeeding

It is currently unknown if ofatumumab is excreted in human breast milk. While many large protein medications like ofatumumab are likely to be broken down in an infant's stomach, the potential for side effects in a nursing child has not been fully determined. Decisions regarding breastfeeding while on this medication should be made in consultation with a healthcare provider, weighing the necessity of the drug for the mother against the potential risks to the infant.

Question 10

What forms and strengths does Ofatumumab come in?

Accepted Answer

Ofatumumab is provided in the following delivery formats:

Subcutaneous Injection: This form is available as a solution in single-dose prefilled autoinjector pens or single-dose prefilled syringes. It is designed for administration into the fatty tissue under the skin.
Intravenous Infusion: This form is available as a concentrated solution in single-dose vials. It must be diluted by a healthcare professional before being administered directly into a vein.

Question 11

What is the FDA approval status of Ofatumumab?

Accepted Answer

The U.S. Food and Drug Administration (FDA) has approved ofatumumab for the treatment of specific autoimmune and oncological conditions. It is currently indicated for:

Relapsing forms of multiple sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Chronic lymphocytic leukemia (CLL) in patients who have not received prior treatment or those whose disease is no longer responding to other therapies.

Ofatumumab carries a boxed warning, the most serious type of warning required by the FDA. This warning concerns the risk of hepatitis B virus (HBV) reactivation. In some patients, the virus has become active again during or after treatment, which can lead to severe liver problems, liver failure, or death. Healthcare providers are required to perform blood tests to screen for HBV infection before starting treatment and must monitor patients with a history of the virus for signs of reactivation.

The FDA has also issued safety communications regarding the risk of Progressive Multifocal Leukoencephalopathy (PML). PML is a rare but serious brain infection caused by a virus that can occur in patients with weakened immune systems. Patients are monitored for new or worsening neurological symptoms while taking this medication. There are no Risk Evaluation and Mitigation Strategies (REMS) currently required for ofatumumab, but it must be administered according to specific safety guidelines to manage infusion or injection-related reactions.

Question 12

What should I know about Ofatumumab and cost?

Accepted Answer

Factors Affecting Cost

The price of ofatumumab can vary based on several factors:

Brand Name: Ofatumumab is available as Kesimpta (for multiple sclerosis) and Arzerra (for chronic lymphocytic leukemia). The pricing and billing structures for these brands differ.
Administration: Kesimpta is a subcutaneous injection that patients often self-administer at home, while Arzerra is an intravenous infusion given by healthcare professionals in a clinic or hospital. Infusion-related costs may include facility fees.
Insurance Coverage: Most insurance plans, including Medicare and private insurers, cover ofatumumab, though they often require prior authorization. Your specific plan determines your copay, coinsurance, and deductible responsibilities.

Financial Assistance

Because ofatumumab is a specialty biologic medication, manufacturers and other organizations may offer support to help manage costs:

Patient Assistance Programs: Manufacturers often provide programs for eligible patients who are uninsured or underinsured to receive the medication at a reduced cost or for free.
Copay Cards: For patients with commercial insurance, copay savings cards may be available to reduce out-of-pocket expenses.

Patients should consult with their healthcare provider, insurance company, or a specialty pharmacy to determine the exact cost of their treatment plan.

Ofatumumab

📋Overview

How It Works

Uses

Brand Names

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ofatumumab

Hospitals.net Disclosure